Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price is back in rally mode. It is still early in the game, but the Q2 results ...

After a strong performance in 2025, Johnson & Johnson is starting the new year right.

Johnson & Johnson (NYSE:JNJ – Free Report) had its target price lifted by Bank of America from $161.00 to $175.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a ...

Johnson & Johnson’s post-Kenvue shift boosts growth and free cash flow, with an elite balance sheet but mixed revisions.

Members of Congress have traded $JNJ stock 22 times in the past 6 months. Of those trades, 11 have been purchases and 11 have been sales. Here’s a breakdown of ...

Johnson & Johnson trades above 21x forward EPS with $24B in Q3 revenue, and a raised FY25 sales guidance outlook. Read why JNJ stock is downgraded to hold.

CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, ...